Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development
Creative Medical Technology Holdings (NASDAQ: CELZ) has expanded its collaboration with Greenstone Biosciences to enhance its iPSC platform development for diabetes treatment. The partnership will leverage Artificial Intelligence to advance their proprietary hypoimmune iPSC technology, including iPSC-derived pancreatic islet cells currently in clinical trials.
The collaboration aims to identify small molecules that enhance insulin secretion and implement multi-gene editing to develop next-generation hypoimmune iPSC lines with improved stealth, survival, and differentiation capabilities. The company expects this AI-driven approach to reduce R&D time by approximately 50% and generate millions in cost savings.
A key focus is addressing the challenge of immunosuppression in stem cell-based therapies, which can cause severe side effects. The development of multi-gene edited hypoimmune iPSCs aims to eliminate the need for immunosuppression, potentially improving patient outcomes in cell-based regenerative therapies.
Creative Medical Technology Holdings (NASDAQ: CELZ) ha ampliato la sua collaborazione con Greenstone Biosciences per migliorare lo sviluppo della piattaforma iPSC per il trattamento del diabete. La partnership sfrutterà l'intelligenza artificiale per far avanzare la loro tecnologia proprietaria iPSC ipoimmune, comprese le cellule isletiche derivate da iPSC attualmente in sperimentazione clinica.
La collaborazione mira a identificare piccole molecole che incrementano la secrezione di insulina e implementare l'editing multi-genico per sviluppare linee iPSC ipoimmune di nuova generazione con migliori capacità di occultamento, sopravvivenza e differenziazione. L'azienda si aspetta che questo approccio guidato dall'IA riduca il tempo di ricerca e sviluppo di circa il 50% e generi milioni di risparmi.
Un obiettivo chiave è affrontare la sfida dell'immunosoppressione nelle terapie basate su cellule staminali, che può provocare gravi effetti collaterali. Lo sviluppo di iPSC ipoimmune a editing multi-genico mira ad eliminare la necessità di immunosoppressione, migliorando potenzialmente i risultati per i pazienti nelle terapie rigenerative basate su cellule.
Creative Medical Technology Holdings (NASDAQ: CELZ) ha ampliado su colaboración con Greenstone Biosciences para mejorar el desarrollo de su plataforma iPSC para el tratamiento de la diabetes. La asociación aprovechará la inteligencia artificial para avanzar en su tecnología propietaria de iPSC hipoinmunes, incluidas las células de islote pancreático derivadas de iPSC que actualmente están en ensayos clínicos.
La colaboración busca identificar pequeñas moléculas que mejoren la secreción de insulina e implementar edición de múltiples genes para desarrollar líneas de iPSC hipoinmunes de nueva generación con capacidades mejoradas de camuflaje, supervivencia y diferenciación. La empresa espera que este enfoque impulsado por IA reduzca el tiempo de I+D en aproximadamente un 50% y genere millones en ahorros.
Un enfoque clave es abordar el desafío de la inmunosupresión en las terapias basadas en células madre, que pueden causar efectos secundarios graves. El desarrollo de iPSCs hipoinmunes editadas por múltiples genes tiene como objetivo eliminar la necesidad de inmunosupresión, mejorando potencialmente los resultados de los pacientes en terapias regenerativas basadas en células.
Creative Medical Technology Holdings (NASDAQ: CELZ)는 당뇨병 치료를 위한 iPSC 플랫폼 개발을 강화하기 위해 Greenstone Biosciences와의 협력을 확장했습니다. 이 파트너십은 인공지능을 활용하여 임상 시험 중인 iPSC 유래 췌도 섬세포를 포함한 독점적인 하이포면역 iPSC 기술을 발전시킬 것입니다.
협력은 인슐린 분비를 증가시키는 작은 분자를 식별하고 다중 유전자 편집을 구현하여 stealth, 생존 및 분화 능력이 향상된 차세대 하이포면역 iPSC 계통을 개발하는 것을 목표로 합니다. 회사는 이 AI 기반 접근 방식이 연구 및 개발 시간을 약 50% 줄일 것으로 예상하며 수백만 달러의 비용 절감 효과를 기대하고 있습니다.
핵심 초점은 세포 기반 치료법에서 면역 억제의 도전을 해결하는 것으로, 이는 심각한 부작용을 초래할 수 있습니다. 다중 유전자 편집된 하이포면역 iPSC의 개발은 면역 억제의 필요성을 없애고, 세포 기반 재생 치료에서 환자 결과를 개선할 수 있을 것으로 보입니다.
Creative Medical Technology Holdings (NASDAQ: CELZ) a élargi sa collaboration avec Greenstone Biosciences pour améliorer le développement de sa plateforme iPSC pour le traitement du diabète. Le partenariat exploitera l'intelligence artificielle pour faire progresser sa technologie iPSC hypoimmune propriétaire, y compris les cellules îlots pancréatiques dérivées d'iPSC actuellement en essais cliniques.
Cette collaboration vise à identifier de petites molécules qui améliorent la sécrétion d'insuline et à mettre en œuvre un éditing multi-génique afin de développer des lignées iPSC hypoimmunes de nouvelle génération avec de meilleures capacités d'invisibilité, de survie et de différenciation. L'entreprise s'attend à ce que cette approche pilotée par l'IA réduise le temps de R&D d'environ 50% et génère des millions d'économies.
Un point clé est de relever le défi de l'immunosuppression dans les thérapies basées sur les cellules souches, qui peuvent provoquer des effets secondaires graves. Le développement d'iPSCs hypoimmunes à édition multi-génique vise à éliminer le besoin d'immunosuppression, améliorant potentiellement les résultats pour les patients dans les thérapies régénératives basées sur les cellules.
Creative Medical Technology Holdings (NASDAQ: CELZ) hat seine Zusammenarbeit mit Greenstone Biosciences ausgeweitet, um die Entwicklung seiner iPSC-Plattform für die Diabetesbehandlung zu verbessern. Die Partnerschaft wird Künstliche Intelligenz nutzen, um ihre proprietäre hypoimmun iPSC-Technologie voranzutreiben, einschließlich der derzeit in klinischen Studien getesteten iPSC-abgeleiteten Pankreasinseln.
Die Zusammenarbeit zielt darauf ab, kleine Moleküle zu identifizieren, die die Insulinsekretion steigern, und eine Multi-Gen-Crispr-Technik umzusetzen, um nächste Generationen von hypoimmunen iPSC-Linien mit verbesserten Fähigkeiten für Tarnung, Überleben und Differenzierung zu entwickeln. Das Unternehmen erwartet, dass dieser KI-gesteuerte Ansatz die F&E-Zeit um etwa 50% verkürzt und Millionen an Kosteneinsparungen generiert.
Ein Schwerpunkt liegt auf der Bewältigung der Herausforderung der Immunsuppression bei Stammzelltherapien, die schwere Nebenwirkungen verursachen kann. Die Entwicklung von multi-gen-editierten hypoimmunen iPSCs zielt darauf ab, die Notwendigkeit der Immunsuppression zu eliminieren und somit die Patientenergebnisse in zellbasierten regenerativen Therapien potenziell zu verbessern.
- AI integration expected to reduce R&D time by 50% and save millions in costs
- Development of technology that could eliminate need for immunosuppression in treatments
- Current iPSC-derived pancreatic islet cells already in clinical trials
- Expansion of platform applications to multiple regenerative therapies
- Current treatments still require immunosuppression with potential severe side effects including mortality
- Technology is still in development phase with no guaranteed success
PHOENIX, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical”), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced an expanded agreement with Greenstone Biosciences Inc. (“Greenstone”) to leverage Artificial Intelligence (AI) in further developing its human induced pluripotent stem cell (iPSC) platform for diabetes treatment.
This strategic collaboration extends the progress made on Creative Medical’s proprietary hypoimmune iPSC technology, including its iPSC-derived pancreatic islet cells. These innovative cell lines, developed from Good Manufacturing Practice (GMP) grade human perinatal cells, are currently being used in clinical trials. By integrating AI-driven drug discovery, the partnership aims to identify small molecules that enhance insulin secretion, further refining the therapeutic potential of Creative Medical’s hypoimmunogenic iPSC-derived pancreatic islet cells. Additionally, the program will implement multi-gene editing to develop next generation hypoimmune iPSC lines with enhanced stealth, survival, and differentiation capabilities. These advancements will not only optimize pancreatic islet cell function but also expand the platform’s applications to other regenerative therapies, addressing critical unmet medical needs.
Addressing a Major Clinical Challenge
One of the most pressing challenges in stem cell-based therapies is the requirement for immunosuppression, which can lead to severe side effects, including mortality. By refining hypoimmune iPSC lines through AI-guided development, Creative Medical is actively working to overcome these barriers, paving the way for safer and more effective cell-based treatments for diabetes and other chronic conditions.
Leadership Perspective
“Creative Medical is at the forefront of regenerative medicine, and our extended partnership with Greenstone Biosciences marks a significant milestone in our mission to develop transformative therapies,” said Timothy Warbington, President and CEO of Creative Medical.
“Dr. Wu and his team at Greenstone have been instrumental in validating and advancing our proprietary iPSC platform. By incorporating AI-driven methodologies, we estimate that this program will reduce R&D time by approximately
Advancing Multi-Gene Edited Hypoimmune iPSCs
The next phase of development focuses on multi-gene edited hypoimmune iPSCs—cells engineered with precise modifications to evade immune detection, improve survival, and optimize therapeutic potential. These cutting-edge advancements offer the potential to eliminate the need for immunosuppression, significantly improving patient outcomes in cell-based regenerative therapies.
As Creative Medical continues to push the boundaries of regenerative medicine, this collaboration reinforces its commitment to leveraging AI and genetic engineering to address some of the most pressing challenges in modern healthcare.
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc. is a clinical-stage biotechnology company dedicated to developing groundbreaking regenerative therapies using stem cell and immune modulation technologies. The company’s pipeline targets a range of conditions, with a focus on diabetes, autoimmune disorders, orthopedic and neurological diseases. For more information, visit www.creativemedicaltechnology.com.
Forward-Looking Statements
This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements reflect the Company’s current views but are not guarantees of future results.
Contact:
Creative Medical Technology Holdings, Inc.
IR@CreativeMedicalTechnology.com
Investor Relations:
Devin Sullivan, Managing Director
The Equity Group Inc.
dsullivan@equityny.com
FAQ
What is the purpose of CELZ's expanded collaboration with Greenstone Biosciences?
How much R&D time reduction does CELZ expect from the AI-driven development?
What is the main clinical challenge CELZ is trying to address with this technology?
What are the key benefits of CELZ's multi-gene edited hypoimmune iPSCs?
What is the current development stage of CELZ's iPSC-derived pancreatic islet cells?
